Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
FYou can find bargains out there, Ovb plan to bring novel drugs to the market in 2020
But what is crazy is they hold plenty of cash, yet still have a stake in a £5 billion very liquid company Polymetal who trades on the FTSE 100
worth a current £14.8 mil next to a £8.8 mil cap.
The market currently values this stock at a massive discount to NAV
Ovoca Bio plc's Libicore (BP-101) Meets Primary/Secondary Endpoints in Phase 3 Trial for Hypoactive Sexual Desire Disorder Ahead of Time
-- Phase 3 study of Libicore (BP-101) for hypoactive sexual desire disorder (HSDD) in premenopausal women met the pre-specified primary efficacy endpoint of improvement in number of sexually satisfying events:
o In the trial, Libicore (BP-101) showed a statistically significant increase in the number of satisfying sexual events (SSEs) versus placebo (difference in the mean increase in SSEs of 1.83 (95% CI of 0.28-3.39) at the tested daily dose of 2.52mg (p = 0.016)
-- Statistically significant results versus placebo also were seen in the key registration endpoints of:
o Female Sexual Function Index: Desire Domain (FSFI-D) showed a statistically significant mean increase of 1.14 (0.94-1.34) for Libicore (BP-101) vs. 0.58 (0.38 - 0.78) on placebo, p=0.0001; and,
o The Female Sexual Distress Scale - revised (FSDS-R) Item 13 showed a statistically significant mean reduction of -1.2 (-1.4 to -1.0) vs. -0.7 (-0.9 to -0.5), p=0.0019.
-- The pivotal clinical trial, evaluating the efficacy and safety of Libicore (BP-101) versus placebo was stopped early based on the achievement of pre-specified efficacy criteria.
Over the pond
65p here equivalent
23.6 eq .